1. Pink Sheet
  2. >>Market Access

Trump's Greatest Hits: Drug Price Controls As Part Of The Repertoire

 
• By Cathy Kelly

President's pledge to merge drug pricing control with a revamp of the Affordable Care Act wins applause at Kentucky rally, where the president reeled through a number of his populist issues, even as the idea makes scant legislative progress.

Donald Trump

Legislation establishing prescription drug price controls through a government-run "competitive bidding" process will be included in one of the bills that will repeal and replace the Affordable Care Act (ACA), President Donald Trump promised at a rally in Louisville, Ky. March 20.

Trump raised drug pricing at the campaign-style rally as one of his now-familiar populist issues, which also includes revoking the ACA, immigration reform, new trade deals and a loosening of environmental restrictions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By Cathy Kelly

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.